GSK_ Annual_Report_2021-22

Message from the Managing Director Dear Shareholders, I am pleased to inform you that your Company has adapted to a challenging milieu to continue to deliver on its ambition for patients and value for shareholders. During the year, your Company made significant progress towards improving the health of people in India. In 2021, that included nearly a billion doses of medicines and over 4.5 million doses of vaccines (source: IQVIA). Your Company is poised to deliver a step- change in growth and positively impact the health of millions through the General Medicines, Vaccines and Specialty portfolios to get #AheadTogether of disease. Topline growth was driven by some of the category-leading General Medicines brands such as Calpol and Augmentin. Your Company’s continued leadership in Dermatology, despite physical distancing, was propelled by focus brands. Your Company maintained leadership in the Vaccines self-pay market and continued to allow severe asthma patients to breathe easy with Nucala. Apart from engaging Healthcare Professionals (HCPs), your Company initiated disease awareness campaigns that featured the likes of MS Dhoni, former captain of the Indian cricket team, Kareena Kapoor Khan, leading Indian actress, and Neha Kakkar, a playback singer. The pandemic posed a multitude of challenges. With patient outcomes at stake, your Company responded with agility and determination to rise to these challenges. Your Company’s pharmaceutical manufacturing team worked round the clock to fulfil the rise in demand for our key brands. This effort ensured that patients continued to have access to important medication during the pandemic. Your Company’s business strategy focused on building a resilient product portfolio, aligned with manufacturing capabilities and HCP engagement enhanced by adoption of digitalisation and emerging technologies. Strengthening your Company’s vaccine product portfolio formed a significant part of our approach. The launch of Fluarix Tetra transformed the flu vaccine category in the country, with very high rates of recommendations by HCPs. Despite not being a first mover in this vaccine category, your Company has successfully gained the position of a market leader. Your Company has been continuously bolstering digital capabilities and virtual brand presence through focused investments. During the pandemic, your Company’s field force remained active on the ground by effectively using digital channels, to engage remotely with HCPs. The digital infrastructure ensured that touch points could be increased through enhanced use of tele-calling and webinars coupled with the adoption of digital platforms such as Veeva Engage and the HCP Persona Tool. The resilience and commitment of your Company, the robustness of the operating models and the product portfolio driven by our focus brands is conducive to growth and unlocking shareholder value. Your Company strives to maintain an inclusive workplace, which is supported by a strong culture of progress and belonging, with 91% of our employees responding positively to our annual culture survey. As your Company embarks on a journey of navigating another exciting year of robust growth, I would like to extend my heartfelt gratitude to all our investors, employees and shareholders. Regards, Sridhar Venkatesh #AheadTogether 3 Financial Statements Statutory Reports Strategic Priorities Corporate Overview